Dihydroergocryptine in the management of senile psycho-organic syndrome.
A double-blind, placebo-controlled, randomized study is described of an assessment of the efficacy and relative safety of the ergot alkaloid, dihydroergocryptine, on 52 patients with mild organic brain syndrome over a period of three months using a series of neurophysiological tests. The results indicated that short-term treatment with the alkaloid improved memory impairment. The side-effects were mild and transient in both the dihydroergocryptine and placebo groups and there were no alterations in blood chemistry.
Scarzella
L
L
Department of Neurology, University of Turin, Italy.
Bono
G
G
Bergamasco
B
B
D000368:Aged; D004088:Dihydroergotoxine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008570:Memory, Short-Term / Q000187:drug effects; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D009483:Neuropsychological Tests
D004088:Dihydroergotoxine